These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 33684595)

  • 1. Continuous infusion versus intermittent administration of meropenem in critically ill patients (MERCY): A multicenter randomized double-blind trial. Rationale and design.
    Monti G; Galbiati C; Toffoletto F; Calabrò MG; Colombo S; Ferrara B; Giardina G; Lembo R; Marzaroli M; Moizo E; Mucci M; Pasculli N; Plumari VP; Scandroglio AM; Tozzi M; Momesso E; Boffa N; Lobreglio R; Montrucchio G; Guarracino F; Benedetto U; Biondi-Zoccai G; D'Ascenzo F; D'Andrea N; Paternoster G; Ananiadou S; Ballestra M; De Sio A; Pota V; Cotoia A; Della Selva A; Bruni A; Iapichino G; Bradić N; Corradi F; Gemma M; Nogtev P; Petrova M; Agrò FE; Cabrini L; Forfori F; Likhvantsev V; Bove T; Finco G; Landoni G; Zangrillo A;
    Contemp Clin Trials; 2021 May; 104():106346. PubMed ID: 33684595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous vs Intermittent Meropenem Administration in Critically Ill Patients With Sepsis: The MERCY Randomized Clinical Trial.
    Monti G; Bradic N; Marzaroli M; Konkayev A; Fominskiy E; Kotani Y; Likhvantsev VV; Momesso E; Nogtev P; Lobreglio R; Redkin I; Toffoletto F; Bruni A; Baiardo Redaelli M; D'Andrea N; Paternoster G; Scandroglio AM; Gallicchio F; Ballestra M; Calabrò MG; Cotoia A; Perone R; Cuffaro R; Montrucchio G; Pota V; Ananiadou S; Lembo R; Musu M; Rauch S; Galbiati C; Pinelli F; Pasin L; Guarracino F; Santarpino G; Agrò FE; Bove T; Corradi F; Forfori F; Longhini F; Cecconi M; Landoni G; Bellomo R; Zangrillo A;
    JAMA; 2023 Jul; 330(2):141-151. PubMed ID: 37326473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A protocol for a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis: BLING III.
    Lipman J; Brett SJ; De Waele JJ; Cotta MO; Davis JS; Finfer S; Glass P; Knowles S; McGuinness S; Myburgh J; Paterson DL; Peake S; Rajbhandari D; Rhodes A; Roberts JA; Shirwadkar C; Starr T; Taylor C; Billot L; Dulhunty JM
    Crit Care Resusc; 2019 Mar; 21(1):63-68. PubMed ID: 30857514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial.
    Dulhunty JM; Brett SJ; De Waele JJ; Rajbhandari D; Billot L; Cotta MO; Davis JS; Finfer S; Hammond NE; Knowles S; Liu X; McGuinness S; Mysore J; Paterson DL; Peake S; Rhodes A; Roberts JA; Roger C; Shirwadkar C; Starr T; Taylor C; Myburgh JA; Lipman J;
    JAMA; 2024 Aug; 332(8):629-637. PubMed ID: 38864155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A protocol for a multicentre randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients with severe sepsis: the BLING II study.
    Dulhunty JM; Roberts JA; Davis JS; Webb SA; Bellomo R; Gomersall C; Shirwadkar C; Eastwood GM; Myburgh J; Paterson DL; Starr T; Udy AA; Paul SK; Lipman J; ;
    Crit Care Resusc; 2013 Sep; 15(3):179-85. PubMed ID: 23944203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis.
    Dulhunty JM; Roberts JA; Davis JS; Webb SA; Bellomo R; Gomersall C; Shirwadkar C; Eastwood GM; Myburgh J; Paterson DL; Starr T; Paul SK; Lipman J;
    Am J Respir Crit Care Med; 2015 Dec; 192(11):1298-305. PubMed ID: 26200166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.
    Roberts JA; Kirkpatrick CM; Roberts MS; Robertson TA; Dalley AJ; Lipman J
    J Antimicrob Chemother; 2009 Jul; 64(1):142-50. PubMed ID: 19398460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Meropenem Extended Versus Intermittent Infusion Dosing Protocol in Critically Ill Patients.
    Ahmed N; Jen SP; Altshuler D; Papadopoulos J; Pham VP; Dubrovskaya Y
    J Intensive Care Med; 2020 Aug; 35(8):763-771. PubMed ID: 29954243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial.
    Chytra I; Stepan M; Benes J; Pelnar P; Zidkova A; Bergerova T; Pradl R; Kasal E
    Crit Care; 2012 Jun; 16(3):R113. PubMed ID: 22742765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial.
    Dulhunty JM; Roberts JA; Davis JS; Webb SA; Bellomo R; Gomersall C; Shirwadkar C; Eastwood GM; Myburgh J; Paterson DL; Lipman J
    Clin Infect Dis; 2013 Jan; 56(2):236-44. PubMed ID: 23074313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Impact of an Optimized PK/PD Target Attainment of Piperacillin-Tazobactam vs. Meropenem on the Trend over Time of SOFA Score and Inflammatory Biomarkers in Critically Ill Patients Receiving Continuous Infusion Monotherapy for Treating Documented Gram-Negative BSIs and/or VAP.
    Gatti M; Rinaldi M; Tonetti T; Siniscalchi A; Viale P; Pea F
    Antibiotics (Basel); 2024 Mar; 13(4):. PubMed ID: 38666972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration?
    Roberts JA; Roberts MS; Robertson TA; Dalley AJ; Lipman J
    Crit Care Med; 2009 Mar; 37(3):926-33. PubMed ID: 19237898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and Pharmacodynamic Efficacies of Continuous versus Intermittent Administration of Meropenem in Patients with Severe Sepsis and Septic Shock: A Prospective Randomized Pilot Study.
    Zhao HY; Gu J; Lyu J; Liu D; Wang YT; Liu F; Zhu FX; An YZ
    Chin Med J (Engl); 2017 May; 130(10):1139-1145. PubMed ID: 28485312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of studies on extended versus standard infusion of beta-lactam antibiotics.
    Chen M; Buurma V; Shah M; Fahim G
    Am J Health Syst Pharm; 2019 Sep; 76(18):1383-1394. PubMed ID: 31505562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient Data from Randomized Trials.
    Roberts JA; Abdul-Aziz MH; Davis JS; Dulhunty JM; Cotta MO; Myburgh J; Bellomo R; Lipman J
    Am J Respir Crit Care Med; 2016 Sep; 194(6):681-91. PubMed ID: 26974879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence of antimicrobial resistance to piperacillin/tazobactam or meropenem in the ICU: Intermittent versus continuous infusion. A retrospective cohort study.
    Dhaese SAM; De Kezel M; Callant M; Boelens J; De Bus L; Depuydt P; De Waele JJ
    J Crit Care; 2018 Oct; 47():164-168. PubMed ID: 30005302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial.
    Brunkhorst FM; Oppert M; Marx G; Bloos F; Ludewig K; Putensen C; Nierhaus A; Jaschinski U; Meier-Hellmann A; Weyland A; Gründling M; Moerer O; Riessen R; Seibel A; Ragaller M; Büchler MW; John S; Bach F; Spies C; Reill L; Fritz H; Kiehntopf M; Kuhnt E; Bogatsch H; Engel C; Loeffler M; Kollef MH; Reinhart K; Welte T;
    JAMA; 2012 Jun; 307(22):2390-9. PubMed ID: 22692171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis.
    Abdul-Aziz MH; Sulaiman H; Mat-Nor MB; Rai V; Wong KK; Hasan MS; Abd Rahman AN; Jamal JA; Wallis SC; Lipman J; Staatz CE; Roberts JA
    Intensive Care Med; 2016 Oct; 42(10):1535-1545. PubMed ID: 26754759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial.
    Shehabi Y; Sterba M; Garrett PM; Rachakonda KS; Stephens D; Harrigan P; Walker A; Bailey MJ; Johnson B; Millis D; Ding G; Peake S; Wong H; Thomas J; Smith K; Forbes L; Hardie M; Micallef S; Fraser JF; ;
    Am J Respir Crit Care Med; 2014 Nov; 190(10):1102-10. PubMed ID: 25295709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.